Stock Analysis on Net

Humana Inc. (NYSE:HUM)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Humana Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income 739 (540) 830 956 1,238 (18) 1,193 697 930 (13) 1,531 588 828 (274) 1,340 1,828 473 512 689 940 566
Gain on sale of Gentiva Hospice 3 (240)
(Gain) loss on investment securities, net (1) 5 4 (15) 60 69 (1) 61 76 112 104 (76) (10) (142) (645) (2) (49) (39) (18) (7) 2
Gain on Kindred at Home equity method investment (1,129)
Equity in net (earnings) losses 24 24 12 10 17 5 (3) (2) 4 4 (15) (33) (21) (6) (35) (25) (8) 2 (1) (12) (3)
Stock-based compensation 45 33 53 51 38 43 80 50 43 48 48 45 39 52 47 46 36 44 43 43 33
Depreciation 226 222 218 210 200 194 186 188 181 172 160 155 153 138 138 128 124 123 142 122 118
Amortization 16 16 17 16 18 23 28 21 24 22 21 15 15 22 23 22 21 17 17 18 18
Impairment on property and equipment 33 175 31 104 4 140
Impairment of intangible assets 55
Deferred income taxes (167) (67) (200) 167 15 198 (3) 183 (21)
Receivables (1,890) (211) (395) 1,702 (1,433) (65) 1,744 (373) (1,360) 14 991 (236) (1,049) (3) 1,103 (232) (953) (211) 56 1,063 (940)
Other assets 97 (383) 206 (234) (907) 2 190 (27) (628) (15) 403 216 (1,095) 966 577 (654) (1,470) (216) 882 (446) (102)
Benefits payable 1,488 45 (108) 224 754 27 (413) 272 1,089 (469) 273 (166) 466 (65) 228 890 1,086 (216) 378 (182) 1,162
Other liabilities (422) 802 209 68 (238) 239 138 (230) (103) (31) 508 (150) (151) (658) (1,010) 1,064 1,203 303 284 (132) 16
Unearned revenues 35 (7,270) 158 158 6,934 (5,726) 5,748 (24) 34 19 (89) (2) 7 31 21 (8) 27 (27) (38) 29
Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions (692) (7,017) 70 1,918 5,110 (5,523) 7,407 (382) (968) (482) 2,086 (338) (1,822) 271 919 1,060 (107) (367) 1,562 303 165
Other 33 60 17 30 6 40 (1) 19 12 26 29 4 (19) 24 28 10 (13) 37 8 27 18
Adjustments to reconcile net income to net cash provided by (used in) operating activities (316) (6,594) 422 2,220 5,449 (5,109) 7,260 262 (628) (83) 1,304 (228) (1,665) 557 475 1,239 1 1,753 494 330
Net cash provided by (used in) operating activities 423 (7,134) 1,252 3,176 6,687 (5,127) 8,453 959 302 (96) 2,835 360 (837) 283 1,815 3,067 474 512 2,442 1,434 896
Proceeds from sale of Gentiva Hospice, net (7) 2,708
Acquisitions, net of cash and cash equivalents acquired (14) (10) (34) (116) (73) (44) (126) (93) (74) (228) (3,634) (202) (123) (709)
Purchases of property and equipment, net (177) (73) (234) (264) (223) (258) (288) (279) (295) (371) (326) (329) (290) (296) (250) (226) (192) (230) (210) (157) (139)
Purchases of investment securities (1,259) (4,186) (629) (1,424) (1,313) (1,309) (1,501) (1,078) (2,161) (624) (1,266) (1,587) (3,720) (1,895) (1,766) (3,005) (2,459) (2,231) (995) (960) (2,175)
Proceeds from maturities of investment securities 645 407 308 310 267 151 267 359 588 494 476 935 692 1,486 1,855 910 735 452 387 497 397
Proceeds from sales of investment securities 391 2,980 4 761 50 455 616 69 1,294 627 499 468 1,953 650 13 669 1,415 1,208 252 564 2,062
Net cash (used in) provided by investing activities (414) (882) (585) (733) (1,292) (1,012) 1,676 (1,022) (648) (102) (4,251) (715) (1,488) (55) (148) (1,652) (1,210) (801) (566) (56) 145
Receipts (withdrawals) from contract deposits, net 499 (1,653) (1,029) 513 2,997 (1,794) 711 601 2,475 (911) (578) 168 1,015 (665) (663) (185) 574 (634) (462) (81) 554
Proceeds from issuance of senior notes, net 2,232 1,329 1,215 1,238 744 2,984 (2) 1,090 987
Repayments of senior notes (113) (1,370) (289) (60) (1,000) (400) (400)
Proceeds from issuance (repayments) of commercial paper, net (644) (1,407) 1,380 415 (177) 284 (242) (153) (265) 159 (315) (95) 603 274 (177) 198 (2) (2) (373) 17
Proceeds from short-term borrowings 100
Repayment of short-term borrowings (100)
Proceeds from term loan 2,000 500 1,000
Repayment of term loan (500) (2,000) (1,928) (150) (1,000) (650)
Debt issue costs (5) (3) (4) (4) (1) (1) (2) (8) (21)
Change in book overdraft (20) 107 (211) 51 108 61 (154) 74 (9) 86 4 (107) 23 106 (96) 140 (55) (48) 69 50 (17)
Common stock repurchases (717) (571) (379) (529) (94) (1,064) (4) (4) (1,024) (43) (3) (3) (30) (1,790) (5) (8) (17) (60) (1,000) (10)
Dividends paid (109) (111) (109) (111) (100) (101) (100) (100) (91) (91) (90) (90) (83) (84) (83) (83) (73) (75) (74) (74) (68)
Other (29) (16) (15) (14) (106) 22 (2) 2 (13) 18 (2) 4 1 19 2 9 19 35 5 1 17
Net cash provided by (used in) financing activities 1,207 (2,438) (1,733) 36 3,279 (2,358) (1,791) 419 1,816 (712) 2,342 (144) 1,529 (3,540) (845) (306) 2,736 (1,184) (1,127) (477) 493
Increase (decrease) in cash and cash equivalents 1,216 (10,454) (1,066) 2,479 8,674 (8,497) 8,338 356 1,470 (910) 926 (499) (796) (3,312) 822 1,109 2,000 (1,473) 749 901 1,534

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Humana Inc. net cash provided by (used in) operating activities decreased from Q3 2023 to Q4 2023 but then increased from Q4 2023 to Q1 2024 not reaching Q3 2023 level.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Humana Inc. net cash (used in) provided by investing activities decreased from Q3 2023 to Q4 2023 but then increased from Q4 2023 to Q1 2024 exceeding Q3 2023 level.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Humana Inc. net cash provided by (used in) financing activities decreased from Q3 2023 to Q4 2023 but then increased from Q4 2023 to Q1 2024 exceeding Q3 2023 level.